23 Mar DePuy Synthes Acquires CUPTIMIZE™ Hip-Spine Analysis, Providing Technology to Help Surgeons Better Understand, Measure and Address Pelvic Tilt
Latest Addition to VELYS™ Digital Surgery Platform, CUPTIMIZE™ Hip-Spine Analysis is a Simple, X-Ray-Based Digital Solution that uses patient-specific data to help surgeons assess dislocation risk, with the aim of enhancing outcomes
Used with DePuy Synthes’ hip implants, this technology aims to deliver a comprehensive procedural solution to advance patient outcomes
Palm Beach Gardens, FL. – March 21, 2022 – Today, Johnson & Johnson MedTech* announced that DePuy Synthes,** The Orthopaedics Company of Johnson & Johnson, has acquired CUPTIMIZE™ Hip-Spine Analysis, giving surgeons an easy-to-use tool to better understand and address the impact of abnormal motion between the spine and pelvis in some patients who require total hip arthroplasty (THA). CUPTIMIZE Hip-Spine Analysis (CUPTIMIZE Analysis) enhances the surgical planning capabilities of VELYS™ Hip Navigation, one of the solutions within DePuy Synthes’ VELYS Digital Surgery platform of connected technologies.
Abnormal pelvic tilt is present in approximately 20 percent of patients who require total hip arthroplasty.1 It is estimated that up to 50 percent of revision THAs are avoidable and of those, 48 percent are due to suboptimal cup positioning.2 A hip-spine analysis that enables the surgeon to quantify changes in pelvic tilt may provide for optimal cup positioning which may help reduce the risk of dislocation related to pelvic tilt.3
Unlike other technologies, CUPTIMIZE Hip-Spine Analysis does not rely on advanced imaging or engineering staff. Instead, a simple, digital screening tool analyzes x-rays of the patient when standing and sitting to identify abnormal motion between a patient’s spine and pelvis (e.g., pelvic tilt). In conjunction with VELYS Hip Navigation’s intra-operative capabilities, CUPTIMIZE allows surgeons to deliver more personalized care.
“The CUPTIMIZE Analysis is easy to use and allows me to make pre-operative decisions regarding a patient’s unique spinopelvic characteristics in a simple way before surgery,” said Dr. Jonathan Vigdorchik,*** orthopaedic surgeon, New York, NY. “It is an efficient tool to execute my plan during the operation.”
VELYS Hip Navigation provides an integrated solution for pre-operative planning and intra-operative execution that provides actionable, real-time data to personalize hip replacement and is designed to improve precision, increase surgical reproducibility, and optimize patient outcomes.
“At DePuy Synthes, we’re focused on addressing unmet needs with advanced technologies to deliver the most personalized care, like VELYS Hip Navigation with the CUPTIMIZE Analysis, with the goal of better outcomes for joint replacement surgery patients,” said Sharrolyn Josse,**** Worldwide President, VELYS Digital Surgery & Capital “This acquisition is one more advancement on our journey to becoming the most personalized and connected orthopaedics company.”
For more information on VELYS Hip Navigation and other enabling technologies from DePuy Synthes, visit here.
About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.
About DePuy Synthes
DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS™ Digital Surgery portfolio, are designed to advance patient care while delivering clinical and economic value to healthcare systems worldwide. Building on our proud product innovation and legacy of industry firsts, we are reimagining the orthopaedic landscape with new advancements in medical technologies and digital surgery across the entire continuum of care to Keep People Moving today and tomorrow. For more information, visit www.depuysynthes.com.
* Comprising the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment.
** DePuy Synthes represents the products and services of DePuy Synthes Sales, Inc., and its affiliates.
*** Dr. Jonathan Vigdorchik is a design surgeon and a paid consultant of an affiliate of DePuy Synthes.
**** Sharrolyn Josse is an employee of Medical Device Business Services, Inc.
- Buckland, Aaron J. MBBS, FRACS, Ethan W. Ayres, MPH, Andrew J. Shimmin, MBBS, FRACS, Jonathan V. Bare, MBBS, FRACS, Stephen J. McMahon, MBBS, FRACS, Jonathan M. Vigdorchik, MD. (2019) Prevalence of Sagittal Spinal Deformity Among Patients Undergoing Total Hip Arthroplasty, DOI: 10.1016/j.arth.2019.08.020.
- D. Novikov, J. J. Mercuri, R. Schwarzkopf, W. J. Long, J. A. Bosco III, J. M. Vigdorchik. Can some early revision total hip arthroplasties be avoided? Bone Joint J 2019;101-B(6 Supple B):97–103
- J. Vigdorchik, N. Eftekhary, A. Elbuluk, M. P. Abdel, A. J. Buckland, R. S. Schwarzkopf, S. A. Jerabek, D. J. Mayman. Evaluation of the spine is critical in the workup of recurrent instability after total hip arthroplasty. Bone Joint J 2019;101-B:817–823.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding CUPTIMIZE Hip-Spine Analysis. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes, Inc, any of the other Johnson & Johnson MedTech Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, or on request from Johnson & Johnson. Neither DePuy Synthes, Inc. / the Johnson & Johnson MedTech Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
© DePuy Synthes 2022. All rights reserved.
Please refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions.
SOURCE: DePuy Synthes, March 21 2022